Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 239

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 15
Chunk 239
---
 in the Pain & Sleep Aids category led by restored supply of the Solpadeine® brand, partially offset by unfavorable impacts across multiple OTC businesses due to soft category consumption, including lower net sales of $12.5 million in the VMS category.

CSCI net sales by product category were as follows:

SalesNine Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeSkin Care$326.1 $333.5 $(7.4)(2.2)%Upper Respiratory209.5 206.0 3.5 1.7 %Healthy Lifestyle180.2 175.2 4.9 2.8 %Pain and Sleep-Aids173.4 158.6 14.9 9.4 %VMS116.2 127.4 (11.2)(8.8)%Women's Health103.3 101.2 2.2 2.2 %Oral Care71.6 75.0 (3.4)(4.6)%Digestive Health30.1 27.0 3.1 11.5 %Other CSCI44.7 81.5 (37.0)(45.3)%Total CSCI$1,255.1 $1,285.5 $(30.4)(2.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $326.1 million decreased 2.2%, inclusive of a 1.2% favorable effect of currency translation, due primarily to soft seasonal consumption trends compared to the prior year and the unfavorable impact of 2.0% from divested businesses and exited product lines. These factors were partially offset by share growth in Compeed® and Sebamed®, despite the soft seasonal trends;

50

Perrigo Company plc - Item 2CSCI

•Upper Respiratory: Net sales of $209.5 million increased 1.7%, inclusive of a 2.6% favorable effect of currency translation, due primarily to improved supply of key products and growth in brand and store brand allergy products. These factors were more than offset by an unfavorable impact of 1.5% from divested businesses and exited product lines, and lower incidence and consumption of cough cold products;

•Healthy Lifestyle: Net sales of $180.2 million increased 2